

Date: 15th August 2025

To, Manager - Listing Compliance National Stock Exchange of India Limited 'Exchange Plaza'. C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 SYMBOL: JSLL	To, Head of the Department, Department of Listing Operation, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400001 SCRIP Code: 544476
--	--

Sub: Investor Presentation under Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Ma'am,

In continuation of our earlier communication dated August 12, 2025, regarding the schedule of the conference call (Group Conference call) to discuss the financial performance of the Company for the Q1 (FY 2025-26), please find enclosed the **Investor Presentation** of the Company for the Q1 (FY 2025-26 pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This presentation is being used during meeting with investors scheduled on August 18, 2025.

You are requested to take the above information on records and disseminate the same on your website.

The Investor Presentation is also being disseminated on Company's website at www.jeenasikho.com/

Thanking you,
Yours faithfully,

For Jeena Sikho Lifecare Limited
Manish Grover
Managing Director
DIN: 07557886
Place: Zirakpur, Punjab
Date: 15-08-2025

JEENA SIKHO LIFECARE LIMITED

120+ AYURVEDA CLINICS & HOSPITALS | FREEDOM FROM 2D DISEASES & DRUGS

Registered Office Address:

SCO-11, Kalgidhar Enclave, Baltana, Zirakpur,
Punjab-140604, 01762-513185
CIN NO.: L52601PB2017PLC046545

Corporate Office Address:


B-26, Opp. Metro Pillar No. 223, Rohtak Road,
New Multan Nagar, Delhi - 110056
Email ID: cs@jeenasikho.com | www.jeenasikho.com

Empowering Holistic Health & Wellness

JEENA SIKHO LIFECARE LIMITED

Jeena Sikho

Shuddhi
AYURVEDA CLINICS & HOSPITALS



120+ Ayurveda Clinics & Hospitals | Freedom from 2D: Disease & Drugs

INVESTOR PRESENTATION
Q1FY26 | AUGUST 2025





Table of Contents

01

QUARTERLY PERFORMANCE HIGHLIGHTS

Key Financial Milestones and Insights

02

INTRODUCTION TO JSLL

Company Overview and Strategic Foundation

03

UNIQUE BUSINESS MODEL POSITIONING

Differentiated Market Approach and Competitive Advantage

04

BREADTH OF OPERATIONS

Reach of Our Operations

05

WAY FORWARD

Vision, Strategy, and Roadmap

06

ANNUAL FINANCIAL HIGHLIGHTS

Key Financial Milestones and Insights



Q1

Quarterly
*Performance
Highlights*




Q1FY26 Performance Highlights

Revenue from Operations


(In ₹ Crore)

▲ 25% QoQ change
▲ 74% YoY change



EBITDA & EBITDA Margin


(In ₹ Crore & %)



PAT & PAT Margin


(In ₹ Crore & %)

▲ 88% QoQ change
▲ 218% YoY change




Revenue-Mix

(In ₹ Crore)



■ Government Panchkarma
■ Private Panchkarma
■ Medicine

Q1FY26 *Income Statement*



(In ₹ Lakhs)


PARTICULARS	Q1FY25	Q4FY25	Q1FY26	YoY CHANGE (%)	QoQ CHANGE (%)
REVENUE FROM OPERATIONS	10,004	13,902	17,429	74%	25%
GROSS PROFIT	8,908	12,616	15,593	75%	23%
GROSS PROFIT MARGIN (%)	89%	91%	89%	42 BPS	-128 BPS
OPERATING EXPENSES	6,443	7,943	7,714	20%	-3%
EBITDA	2,465	4,672	7,879	220%	69%
EBITDA MARGIN (%)	25%	34%	45%	2,056 BPS	1,160 BPS
DEPRECIATION & AMORTISATION	528	880	965	83%	10%
EBIT	1,937	3,792	6,914	257%	82%
FINANCE COST	94	153	166	76%	8%
OTHER INCOME	264	49	107	-60%	117%
PROFIT BEFORE TAXES	2,107	3,688	6,855	225%	86%
TAXES	574	1,007	1,778	210%	77%
PROFIT AFTER TAXES	1,614	2,735	5,131	218%	88%
PROFIT AFTER TAXES MARGIN (%)	16%	20%	29%	1,354 BPS	966 BPS
EARNINGS PER SHARE (₹)	1.30	2.20	4.13	218%	88%

Note: Post migration to mainboard the Company has shifted to Ind AS Accounting Standards

Q1FY26 *Operating Metrics*


IPD Patient Volumes (#)

▲ 34% QoQ change ▲ 46% YoY change




OPD Patient Volumes (# Lakhs)

▲ 29% QoQ change ▲ 68% YoY change




Day Care Volumes (#)

▲ 31% QoQ change ▲ 164% YoY change




OPD, COD & VC Patients (# Lakhs)

▲ 45% QoQ change ▲ 50% YoY change




Video-Call Consultations (#)

▲ 21% QoQ change ▲ 64% YoY change



Management Commentary



We have commenced FY26 on a strong note, delivering robust all-round performance across all key metrics in the first quarter.

Our Revenue for Q1 stood at ₹174 Crores, registering a significant 74% growth YoY and even a notable 25% sequential growth. Revenue growth was broad-based, with both the Services and Products businesses delivering equally strong performances, thereby maintaining our revenue mix in line with the previous year.

Within the Services vertical, strong momentum was driven by higher IPD as well as OPD volumes, aided by the early impact of new operational facilities and incremental bed capacities added over the past year. IPD volumes grew 46% YoY and 34% QoQ, while OPD volumes also rose sharply by 68% YoY and 29% QoQ, contributing significantly to Services topline growth and associated medicine sales.

This Revenue momentum also translated into positive operating leverage, leading to meaningful margin expansion and healthy net profit growth. Our EBITDA margins for the quarter stood at 45% as opposed to 25% in Q1FY25 and 34% in Q4FY25. Our footprint expansion also progressed well, with a notable increase in our overall bed count. While the newly added bed capacity, with 391 beds added in Q1, is yet to contribute materially to revenues, these investments lay a solid foundation for sustainable growth through the remainder of FY26.

Acharya Manish Ji

MANAGING DIRECTOR


We continue to emphasise measured nationwide expansion, deepening our presence across geographies. During the quarter, revenue from the Government Panel business moderated, in line with our strategic shift towards the more profitable Private Panchkarma segment. This focus will also help improve our cash conversion cycle, given the higher receivable cycle in the Government Panel segment. In FY26, our priority remains on scaling Panchkarma services and driving growth in Medicines & OTC sales.

On the product innovation front, we recently launched the 'Pet Yakrit Pleeha Shuddhi Kit', with several more promising products under development, which we expect to roll out in the coming quarters.

In a significant corporate development, we successfully migrated to the mainboard of NSE and BSE from the NSE Emerge platform this month, an important milestone that will enhance our market visibility and strengthen access to a broader pool of investors.


In conclusion, we are confident that our strategic initiatives, combined with our expanded operational capacity, process efficiencies, and innovative service offerings, will continue to drive sustainable growth. We remain committed to strengthening Jeena Sikho's position as a leading player in the healthcare sector and delivering long-term value to all stakeholders.





02

Introduction to
*Jeena Sikho
Lifecare*





An emerging health crises:

Modern healthcare, while advancing rapidly, often brings unintended side effects that can compromise overall well-being. Despite significant investments of time, resources, and trust, many individuals continue to experience persistent health issues and increasing dependency on medications. Environmental factors such as contaminated water, adulterated food, and reduced connection with nature further contribute to a gradual decline in health.

Quick symptomatic treatments frequently address only the surface of these problems, providing temporary relief rather than lasting solutions. This cycle of dependency underscores the need for a more holistic approach

A leap toward true healing:

After years of research and demonstrable outcomes, Acharya Manish Ji advocates for Ayurveda as a principal healthcare approach. Rooted in ancient wisdom and supported by real-world results, Ayurveda emphasizes balance of body, mind, and spirit, aiming to address the root causes of illness rather than merely suppressing symptoms.

Through gentle, non-invasive therapies, Ayurveda offers a path to sustainable health, even for chronic health conditions. Embracing these principles enables individuals to reduce dependency on pharmaceuticals and move toward a healthier, more balanced life

Introduction to *Jeena Sikho Lifecare*

INDIA'S LEADING AYURVEDA HEALTHCARE
SERVICE PROVIDER



55

OPERATIONAL
HOSPITALS



2,179

BEDS OPERATIONAL



391 Beds

RECENTLY ADDED



100+

CITIES & TOWNS
COVERED

61

OPERATIONAL CLINICS &
DAY CARE CENTRES

360

BEDS IN PIPELINE

23

STATES COVERED

330+

SKUS IN AYURVEDA
MEDICINE & PRODUCT
PORTFOLIO



47%

3Y TOP LINE CAGR[^] -
ONE OF THE FASTEST
GROWING HEALTHCARE
ENTERPRISE



71%

ROCE* - CAPITAL-LIGHT
BUSINESS MODEL

*3Y Average ROCE | ^3Y CAGR (FY22-25)



NSE


LISTED ON NSE SINCE
APRIL 2022



Migrated

MIGRATED TO NSE &
BSE MAINBOARD IN
AUGUST 2025

Journey so far




An idea is born

2009

The idea of **Jeena Sikho** was born

ACTIVE HOSPITALS AND CLINICS & DAY CARES (#)



Initial products & medicines business commences

2009

Commenced ayurveda medicine & product sales



Holistic health care services added to the fold

2013

Established **first ayurveda health care centre** in Chandigarh

2017

Jeena Sikho Lifecare was incorporated as a company

2018

Developed the **Shuddhi Project** to setup dedicated ayurveda health care centres

2020

Inaugurated **Derabassi centre – Shuddhi Ayurveda Panchakarma Hospital**

2021

Surpassed **50 operational centres** across the country



Raised growth capital to expand in both verticals

2022

Successfully raised **₹55.5 Cr** from IPO

2023

Opened centres in **Lucknow, Jaipur, Navi Mumbai** among **20 other small-mid centre** across the country

2024


Achieved landmark revenue of **₹324 Cr**

2025

Surpassed **1,600 operational bed capacity** with newly added 573 beds, across total 77 units



About the *founder*



Acharya Manish Ji: Reviving a Nation Through Ayurveda

Fueled by a powerful vision of a Disease-Free, Drug-Free Bharat, Acharya Manish Ji's unwavering faith in Ayurveda took root and flourished. Through years of in-depth research in Ayurveda and Naturopathy, he uncovered what ancient sages always knew – true healing lies in nature, not in chemicals.

Recognizing Ayurveda's ability to treat chronic and critical illnesses without harmful side effects, he pioneered the revolutionary Golden Therapy – a transformative treatment now bringing hope to countless people. Now people have the advantage to pursue good health, a peaceful mind and a nurtured soul, all at once.

More than just treatment, Acharya Ji advocates a national awakening: a Bharat where every individual becomes their own healer. His mantra, “अपना डॉक्टर खुद बनो”, isn't just a slogan – it's a call to reclaim our health, roots, and inner wisdom.


EXTENSIVE EXPERIENCE AND MASTERY

Driven by a passion for natural healing, Acharya Manish Ji has dedicated his life to making ancient Ayurvedic wisdom accessible and practical for modern living. Through Jeena Sikho Lifecare, he has built a nationwide network of wellness centers and clinics, offering personalized care that addresses the root causes of disease. His educational initiatives-ranging from television programs to social media content and community health camps-have empowered lakhs of people to take charge of their health using Ayurveda's principles of detoxification, rejuvenation, and balance.

SOCIETAL IMPACT

Acharya Manish Ji envisions a world where holistic health is not a privilege but a universal right. He is committed to breaking down barriers to Ayurvedic care, expanding its reach both across India and globally. His mission centers on transforming healthcare by combining ancient wisdom with innovative approaches, ensuring that every individual can experience the benefits of natural healing. Through relentless advocacy, quality-driven practices, and a focus on education, Acharya Manish Ji continues to inspire a healthier, more balanced society.

Meet the *JSSL Team*



Dr. Abhishek
Founder (AFI)

Prof. Ish Sharma
MD, Ph.D Ayurveda

Acharya Manish Ji
Naturopathy & Diet
Expert

Dr. BRC
Ph.D, Diabetes

Dr. Neha Sharma
BAMS/ACLS, Autism



Guiding Force behind Jeena Sikho



Mr. Manish Grover

MANAGING DIRECTOR

Ms. Bhavna Grover

WHOLE TIME DIRECTOR

Ms. Shreya Grover

DIRECTOR

Mr. Karanvir Singh Bindra

INDEPENDENT DIRECTOR

Mr. Chandan Kumar Kaushal

INDEPENDENT DIRECTOR

Ms. Priyanka Bansal

INDEPENDENT DIRECTOR



Mr. Nanak Chand

CHIEF FINANCIAL OFFICER

Mr. Gaurav Mohan Garg

BUSINESS DEVELOPMENT HEAD

Mr. Sahil Jain

OPERATIONS HEAD

Dr. Ish Sharma

HEAD-TRAINING DOCTOR

Dr. Avira Gautam

SENIOR DOCTOR

Ms. Smita Chaturvedi

COMPANY SECRETARY

Ms. Akansha Jain

HR HEAD

Mr. Mukesh Grover

ADMINISTRATION HEAD

Mr. Pradeep Kumar Thakur

MANAGER OPERATIONS - CLINIC

Dr. Neha Sharma

DOCTOR

Ms. Namrta Chaudhary

CLIENT SUPPORT CENTRE HEAD



03

Unique Business

Model

Positioning

Superior *Business Model Positioning*

A UNIQUE COMBINATION OF PRODUCT & SERVICE REVENUE STREAM



Ayurveda health care services

- OPERATED OUT OF HOSPITALS & CLINICS THROUGH A HUB & SPOKE MODEL
- CAPEX & OPEX-LIGHT OPERATIONAL STRUCTURE
- SIGNIFICANT OPERATING LEVERAGE BEYOND BREAK-EVEN OCCUPANCY LEVELS OF ASSETS

₹254 Cr

REVENUE (FY25)

54%

CONTRIBUTION (FY25)



Ayurveda health care products

- SALES GENERATION OUT OF COMPANY HEALTH CARE CENTRES, TELE-CALLING CENTRE, AND E-COM
- PRODUCT PORTFOLIO WITH ~85% GROSS MARGINS
- MANUFACTURING OUTSOURCED TO A RELIABLE NETWORK OF THIRD-PARTY MANUFACTURERS
- HEALTHY CASH GENERATION FROM THIS VERTICAL

₹215 Cr

REVENUE (FY25)

46%

CONTRIBUTION (FY25)



Significant synergies between the two verticals


SIGNIFICANT CROSS-SELLING & LEAD-GENERATION OPPORTUNITIES BETWEEN BOTH VERTICALS:

1. MEDICINE/PRODUCT CUSTOMERS VISIT HEALTH CARE CENTRES FOR A MORE HOLISTIC TREATMENT
2. HEALTH CARE CENTRES PATIENT'S CONSUME MEDICINES FOR MEDIUM-TO-LONG TENURE POST-TREATMENT

JSSL's Business Structure



JSSL's Business Verticals



UNIQUE BUSINESS MODEL

1. To benefit from significant operating leverage of services vertical
2. Well-supported by healthy cash-generation from high-margin products vertical
3. Significant cross-selling & synergies between both the verticals

JSLL's *Unique Capital-light Approach*



Low CAPEX per bed

- Setup cost of ₹3-4 lakh per bed (a typical 100 bed facility)
- Setup at custom-made leased facilities
- Limited investments in panchakarma bed & equipment



Mix of own & franchise assets

- 36/116 facilities are under franchisees: typically, clinics & day care are operated by franchisees
- Investment & day-to-day operations run by franchisees
- Ayurveda doctors at franchisees on JSLL's payroll & ayurveda medicines exclusively supplied by JSLL



Unique hub-and-spoke model

- Clinics & day-care facilities feeding sales funnel of hospitals in the vicinity
- OPD footfall driving IPD volumes




Capital-light business model

Resulting in:

1. Superior ROCE's – 71%*
2. Ability to scale rapidly
3. Nurturing a robust balance sheet (debt-free)

*3Y Average ROCE

JSLL's *Flywheel Effect*



Robust Sales Funnel



SOCIAL MEDIA CHANNELS:

[youtube.com/@Chikitsaguru](https://www.youtube.com/@Chikitsaguru)
1.06M subscribers
3.9K videos

[youtube.com/@haveshuddhi](https://www.youtube.com/@haveshuddhi)
519K subscribers
2.8K videos)

[youtube.com/@HIIMSOofficial](https://www.youtube.com/@HIIMSOofficial)
623K subscribers
3.1K videos

[facebook.com/GuruManishAyurveda/](https://www.facebook.com/GuruManishAyurveda/)
328K Likes
1.1M Followers

[facebook.com/HaveShuddhi/](https://www.facebook.com/HaveShuddhi/)
257K Likes
777K Followers

[facebook.com/hiimsofficial](https://www.facebook.com/hiimsofficial)
390K likes
1.6M followers

[facebook.com/shuddhiclinic](https://www.facebook.com/shuddhiclinic)
102K likes
269K followers

[instagram.com/haveshuddhi](https://www.instagram.com/haveshuddhi)
294K followers

[instagram.com/shuddhiclinics](https://www.instagram.com/shuddhiclinics)
282K followers

[instagram.com/hiimsofficial](https://www.instagram.com/hiimsofficial)
788K followers

[instagram.com/chikitsaguru](https://www.instagram.com/chikitsaguru)
764K followers

NATIONAL & REGIONAL TV PRESENCE:



CLIENT SUPPORT CENTRE:

Continuously & proactively in touch with customers through Client Support Centre marketing

- Proactive Social Media Presence
- Client Support Centre Marketing
- Presence on National & Regional TV, Radio, News Papers and Cinema
- E-Com Sales Channel


3

72-HOUR HEALTH CARE CAMPS ORGANISED (Q1FY26)


255

CUMULATIVE VISITORS AT HEALTH CARE CAMPS (Q1FY26)
 Health care camps serving as a direct source of revenue as well as leads for hospitals

CUMULATIVE OPD, COD & VC CUSTOMERS SERVED: (IN LAKHS)



ALL RESULTING IN GROWING IPD VOLUMES: (#)



Health Care Camps

OPD & Medicine Customers

IPD Patients

Attractive *Unit Economics*



Typical CAPEX of a 100-bed facility

Furniture & fixtures:
~₹45-50 lakhs

Medical equipment:
~₹60-65 lakhs

Others-Infra (varying at each facility):
~₹150-250 lakhs

Total: ₹250-350 lakhs

Per bed: ₹3-4 lakhs



OPEX of a 100-bed facility (monthly)

Fixed Costs

Typical team size:

- ~20 ayurveda doctors
- ~80 support-staff
- ~100 contractual staff

₹50-55 lakhs monthly payroll

Rent

₹10-12 lakhs monthly depending upon location

Variable Costs

Minimal consumables, electricity & operating expenditure
~12-15% of sales



Revenue potential

₹8,287/day/bed*
Bundled of Panchakarma service per day per bed

~₹300 lakhs#
monthly revenue potential at 100% occupancy levels of a 100-bed facility

~35%
Approximate break-even occupancy levels as per standard operating expense structure

*Rounded off

#Including sale of medicines



Swift paybacks Superior ROCEs (%)

12-18 months for a hospital to reach 70% (respectable utilization)

Payback period of investment
<6 months, even lesser for smaller hospitals

Positioned for *Leadership*



Insurance & Government Panel


INSURANCE EMPANELMENT'S



GOVERNMENT PANEL

- **Delhi** – CGHS, CAPF, DDA, CBSE, CWC, CSIR, BIS, MMTC, Navodaya
- **Rajasthan** – CGHS, RGHS, ECHS, CAPF
- **Haryana** – CGHS, CAPF, DDA, CBSE, CSIR, CWC, BIS, RGHS
- **Karnataka** - CGHS
- **Uttar Pradesh** – CGHS, CAPF, DDA, CBSE, CWC, CSIR, BIS, MMTC, DGHS
- **Maharashtra** – CGHS, CAPF, AIR INDIA
- **Punjab** – CAPF, CGHS

FINTECH-FINANCING



THE SEVEN CENTRAL ARMED POLICE FORCES



- AR – Assam Rifles
- BSF – Border Security Force
- CISF – Central Industrial Security Force
- CRPF – Central Reserve Police Force
- ITBP – Indo-Tibetan Border Police
- NSG – National Security Guard
- SSB – Sashstra Seema Bal



Doctors & Medical Staff

~532

CERTIFIED
AYURVEDA
DOCTORS

~650

SUPPORTING
HEALTH CARE
PERSONNEL

Incentive structures of doctors aligned to serve patients well & run efficient operations



Franchisees

36

FRANCHISEE
OPERATED
HEALTH CARE
CENTRES

CAPEX &
OPEX

(EX-DOCTOR
PAYROLL) BORNE
BY FRANCHISEE
PARTNER

ENSURING QUALITY THROUGH EXCLUSIVE JSLL TEAM & PRODUCTS

- Ayurveda doctors & medical staff at franchise centres on JSLL's payroll
- Exclusive sales of JSLL's ayurveda product portfolio through bundled offerings (consultation + products)



Patients

Enabling quality & affordable alternate health care solutions

Superior customer support service through dedicated health care contact centre

Patient-centric approach generating repeat business

Word-of-mouth is the best marketing tool

Positioned for *Leadership*

Market leadership

- ~9% share of Jeena Sikho in NABH Accredited Panchakarma Clinics (127 all over India)
- ~9% share of Jeena Sikho in NABH Accredited AYUSH Hospitals (374 all over India)
- Leading organised player in Ayurveda healthcare chain with 45 NABH accredited hospitals & clinics
- Further, additional 3 NABH accreditations for AYUSH Hospitals in pipeline

45 + 3

ACTUAL | IN-PIPELINE

NABH ACCREDITED
HOSPITALS & CLINICS

NABH ACCREDITED DATA AS ON 5TH
AUGUST 2025



Humongous size of opportunity

- India has an estimated ~1.9 million hospital beds as per CDDEP
- There is a large, unserved need for alternate medicine



Corporate governance

1. Consistent & growing dividend payout in FY23, FY24 and FY25
2. Audit committee chaired by an Independent Director
3. Engaging in regular investor communication through presentations & conference calls
4. Migrated to mainboard after meeting all mainboard listing criteria's in August 2025



A hand holding a vibrant orange flower over a wooden table. On the table, there is a metal tray containing several small containers of different colored powders and seeds, along with fresh ginger, green leaves, and other herbs. A green circular graphic with a dashed blue border is in the top right corner. A large, semi-transparent number '04' is overlaid on the left side of the image.

04

Breadth of
Operations

Hub-and-spoke *Geographical Expansion*

55

HOSPITAL

61

CLINICS &
DAYCARE CENTRES

23

STATES

100+

CITIES & TOWNS

2,179

BEDS
OPERATIONAL

391 Beds

RECENTLY
ADDED


360

BEDS IN
PIPELINE

5

FACILITIES IN
PIPELINE

Assam	1 hospital
Bihar	1 hospital 10 franchise
Chandigarh	1 hospital
Chhattisgarh	2 hospital 1 franchise
Delhi	3 hospital 7 clinic 1 franchise
Goa	1 hospital
Gujarat	3 hospital 1 clinic 1 franchise
Haryana	6 hospital 1 clinic 5 franchise
Himachal Pradesh	2 clinics
Jammu and Kashmir	1 franchise
Jharkhand	1 hospital 1 clinic 1 franchise
Karnataka	1 hospital
Maharashtra	4 hospital 1 clinic 4 franchise
Madhya Pradesh	2 hospital 1 clinic 1 franchise
Odisha	2 franchise
Punjab	3 hospital 5 clinic 1 franchise
Rajasthan	10 hospital
Tamil Nadu	1 hospital
Telangana	1 hospital
Tripura	1 franchise
Uttar Pradesh	12 hospital 4 clinic 5 franchise
Uttarakhand	1 hospital 1 franchise
West Bengal	1 hospital 2 clinic 1 franchise





Key Health Care Facilities

*Meerut,
Uttar Pradesh*

SINCE
DEC-2022

612
BEDS

NABH
ACCREDITED



*Lucknow,
Uttar Pradesh*

SINCE
JUN-2022

115
BEDS

NABH
ACCREDITED



*Derabassi,
Punjab nearby
Chandigarh*

SINCE
OCT-2020

113
BEDS

NABH
ACCREDITED



*Navi Mumbai,
Maharashtra*

SINCE
NOV-2022

163
BEDS

NABH
ACCREDITED



*Panchkula,
Haryana*

SINCE
AUG-2024

70
BEDS

NABH
ACCREDITED



*Manesar,
Gurugram*


SINCE
MAY-2025

100
BEDS

NABH
ACCREDITED



Health Care Camps *Case Studies*



We conduct regular health care camps each month

Average ~30% conversion of camp attendees for IPD treatments

Meerut Camp

DATES: 27TH TO 29TH JUNE
STATE NAME: UTTAR PRADESH
DURATION: 3 DAYS

106

VISITORS ATTENDED

~₹56 lakhs

DIRECT BUSINESS GARNERED

Meerut Camp

DATES: 23RD TO 25TH MAY
STATE NAME: UTTAR PRADESH
DURATION: 3 DAYS

78

VISITORS ATTENDED

~₹42 lakhs

DIRECT BUSINESS GARNERED

Meerut Camp

DATES: 24TH TO 27TH APRIL
STATE NAME: UTTAR PRADESH
DURATION: 4 DAYS

71

VISITORS ATTENDED

~₹37 lakhs

DIRECT BUSINESS GARNERED

Meerut Camp

DATES: 28TH FEBRUARY TO 2ND MARCH & 21ST TO 23RD MARCH
STATE NAME: UTTAR PRADESH
DURATION: 3 DAYS

75 + 103

VISITORS ATTENDED

~₹68 lakhs

DIRECT BUSINESS GARNERED

Meerut Camp

DATES: 21ST TO 23RD FEBRUARY
STATE NAME: UTTAR PRADESH
DURATION: 3 DAYS

87

VISITORS ATTENDED

~₹34 lakhs

DIRECT BUSINESS GARNERED

Meerut Camp

DATES: 24TH TO 26TH JANUARY & 27TH TO 29TH DECEMBER
STATE NAME: UTTAR PRADESH
DURATION: 3 DAYS

101 + 76

VISITORS ATTENDED

~₹67 lakhs


DIRECT BUSINESS GARNERED





Research Papers Published by *Jeena Sikho* (1/2)

<p>FEBRUARY-25</p> <p>Management Of Early-Stage Breast Cancer With Ayurveda: A Case Study</p>  <p>CLICK HERE</p>	<p>FEBRUARY-25</p> <p>Effective Management Of Renal Calculi (Mutrashmari) With An Ayurvedic Treatment: A Case Report</p>  <p>CLICK HERE</p>	<p>FEBRUARY-25</p> <p>Revitalizing Fertility: A Case Report On The Ayurvedic Management Of Oligospermia (Shukrakshaya)</p>  <p>CLICK HERE</p>	<p>OCTOBER-24</p> <p>Clinical Evaluation Of Chronic Kidney Disease Management: Integrating Lifestyle Modification And Ayurveda</p>  <p>CLICK HERE</p>	<p>OCTOBER-2024</p> <p>Evaluating The Impact Of Ayurvedic Interventions On Renal Health In Chronic Kidney Disease: A Case Study Analysis</p>  <p>CLICK HERE</p>	<p>DECEMBER-24</p> <p>Integrating Ayurvedic Panchkarma In The Management Of Chronic Kidney Disease: A Clinical Case Report</p>  <p>CLICK HERE</p>
<p>DECEMBER-24</p> <p>Successful Ayurvedic Management Of Chronic Psoriasis (Ekakustha): A Case Report</p>  <p>CLICK HERE</p>	<p>DECEMBER-24</p> <p>Holistic Strategies In Chronic Kidney Disease: Case Report On The Impact Of Ayurvedic Treatment</p>  <p>CLICK HERE</p>	<p>DECEMBER-24</p> <p>Holistic Management Of Gallbladder Stones (Pittashmari): A Case Study</p>  <p>CLICK HERE</p>	<p>NOV-DEC 2024</p> <p>A Case Study For Integrating Ayurvedic Panchkarma Therapies For Management Of Chronic Kidney Disease</p>  <p>CLICK HERE</p>	<p>SEPT-OCT 2024</p> <p>Integrating Ayurveda In Chronic Kidney Disease Management</p>  <p>CLICK HERE</p>	<p>OCTOBER-2024</p> <p>Integrative Management Of Chronic Kidney Disease: A Case Report On The Efficacy Of Ayurvedic Panchkarma Therapy In Advanced CKD</p>  <p>CLICK HERE</p>
<p>JULY-DEC 2024</p> <p>A Case Report On The Integrative Management Of Chronic Kidney Disease: An Ayurvedic Approach</p>  <p>CLICK HERE</p>	<p>JULY-2024</p> <p>Ayurvedic Management Of Stage IV Chronic Kidney Disease</p>  <p>CLICK HERE</p>	<p>NOVEMBER-24</p> <p>Ayurvedic Management Of Stage V Chronic Kidney Disease</p>  <p>CLICK HERE</p>	<p>JAN-JUNE 2024</p> <p>Exploring Ayurvedic Interventions In Chronic Kidney Disease With Hypertension: A Case Report</p>  <p>CLICK HERE</p>	<p>JULY-DEC 2024</p> <p>Evaluating The Efficacy Of Ayurvedic Treatments In Stage V Chronic Kidney Disease: A Case Report</p>  <p>CLICK HERE</p>	





Research Papers Published by *Jeena Sikho* (2/2)

<p>MAY-25</p> <p>Resolving Azoospermia (Shukra Kshaya) with an Ayurvedic Approach</p>  <p>CLICK HERE</p>	<p>MAY-25</p> <p>Integrative Ayurvedic Approach in the Management of Chronic Kidney Disease: A Case Report and Therapeutic Insights</p>  <p>CLICK HERE</p>	<p>MAY-25</p> <p>Comprehensive Approach on Integrative Ayurvedic Strategies in Chronic Kidney Disease: A Case Report</p>  <p>CLICK HERE</p>	<p>MAY-25</p> <p>Ayurvedic Approach Enhancing Renal Health and Wellbeing Inchronic Kidney Disease: A Case Report</p>  <p>CLICK HERE</p>	<p>MAY-25</p> <p>Comprehensive Ayurvedic Approach In the Management of Chronic Kidney Disease: A Case Report"</p>  <p>CLICK HERE</p>	<p>MAY-25</p> <p>Alleviating Rheumatoid Arthritis (Aamvata) through Ayurvedic Medicine and Panchakarma: A Case Study</p>  <p>CLICK HERE</p>
<p>MAY-25</p> <p>Therapeutic Management of Uterine Fibroid/ Garbhashayagata Granthi with Ayurveda</p>  <p>CLICK HERE</p>	<p>MAY-25</p> <p>Management of the Symptoms Of Metastatic Lung Cancer with Ayurveda</p>  <p>CLICK HERE</p>	<p>JUNE-25</p> <p>Charma Rog (Skin Disease) Ekkustha (Psoriasis) Management by Ayurvedic Chikitsa Paddhati (Line of Treatment): A Case Study</p>  <p>CLICK HERE</p>	<p>APRIL-25</p> <p>Integrative Ayurvedic Management of Chronic Kidney Disease Stage V: A Case Study on Therapeutic Efficacy and Patient Outcomes</p>  <p>CLICK HERE</p>	<p>JUNE-25</p> <p>The Great Revert of Uncontrolled Type 2 Diabetes Mellitus with Diabetic Neuropathy by Ayurvedic Intervention: A Case Study Relating Topittaj Prameha</p>  <p>CLICK HERE</p>	<p>JUNE-25</p> <p>Accuracy in the Diagnosis of Diabetes Mellitus with Speedy Reversal through Ayurvedic Management for Prameha Vyadhi: A Case Study</p>  <p>CLICK HERE</p>
<p>JULY-25</p> <p>Ayurvedic Management of Prameha (Diabetes): A Case Study</p>  <p>CLICK HERE</p>	<p>MAY-25</p> <p>Integrative Ayurvedic Management of Chronic Kidney Disease Highlighting the Efficacy of Panchakarma and Ayurvedic Formulations: A Case Report</p>  <p>CLICK HERE</p>	<p>JULY-25</p> <p>Comprehensive Ayurvedic Management of Grade 3 Fatty Liver (Yakrit Vikara): A Case Report</p>  <p>CLICK HERE</p>	<p>JULY-25</p> <p>Effective Management of Chronic Kidney Disease (Vrikka Roga) Using Ayurvedic Treatment: A Case Report</p>  <p>CLICK HERE</p>	<p>JUNE-25</p> <p>Effective Management of Kitibha (Chronic Psoriasis) using Ayurvedic Medicine: A Case Report</p>  <p>CLICK HERE</p>	<p>JUNE-25</p> <p>An Ayurvedic Intervention in Management of Adenomyosis (Bulky Uterus): A Case Report</p>  <p>CLICK HERE</p>



Comprehensive Healthcare Services – 1/2

Health Care Services Offered



IN-PATIENT
DEPARTMENT
(IPD) THROUGH
HOSPITALS



OUT-PATIENT
DEPARTMENT
(OPD) VIA CLINICS
& DAYCARE CENTRES



72-HOUR
HEALTH
CAMPS



PANCHAKARMA
THERAPIES



MEDICAL-KITS



DIET CARE

Comprehensive Healthcare Services – 2/2

Ailments Treated



Thyroid



Obesity
& Weight Loss



Cholesterol



Migraine



Depression



Joint Pain



Back Pain



Eye
Treatment



Acidity &
Gas



Anxiety



Psoriasis



Ulcer



Sexually
Transmitted
Diseases



Fissure



Skincare




Leukoderma



Asthma



Ayurveda *Product Portfolio*



Our Top Selling Products



Existing sales channels

1. CLIENT SUPPORT CENTRES & E-COM
2. AT HEALTH CARE CENTRES

Tapping OTC sales channel at pharmacies with new product launches

330+
SKUS IN
PORTFOLIO

~85%
OVERALL GROSS
MARGINS IN PRODUCT



OTC Product Portfolio




Product Launched

Pet Yakrit Pleeha Shuddhi Kit



Upcoming Products

1. DR. LVR (60 TABLET)
2. DR. KIDNEY CARE (90 TABLETS)
3. DR. MADHU CARE- 60 TABELTS
4. DR. SUKHOON- 60 TABLETS
5. DR. BP CARE- 60 TABLETS
6. NUTRIROZ 32 HERBS
7. NUTRIROZ 42 HERBS
8. GYNO XPERT SYRUP- 500 ML.
9. JOD XPERT OIL- 120 ML
10. RAKT SHUDDHI SYRUP- 500 ML.



ALL PRODUCTS COMPLIANT WITH AYUSH STANDARDS

Client Support Centre Operations

Dedicated health care Client Support Centre for proactive sales & customer support operations:

Driving customer order placement & processing for medicine portfolio

Ensuring repeat business & continued association with customers

Consumer support & grievance redressal


Facilitating sales leads for health care centres

Administering virtual & telephonic consultation through in-house doctors

Guidance on insurance facilities



VIDEO-CALL CONSULTATIONS (#)



Customer *Testimonials*

Comedian Bharti Singh's Mother

When Mrs. Singh was admitted to our facility, allopathic doctors had advised her to take dialyses but she avoided this course of action. Since she began her treatment, she noticed significant improvement in her health. She was on insulin for 20-25 years before she came to Jeena Sikho Lifecare. Within 4 days, she was off the insulin.

[▶ VIEW THE VIDEO](#)

Mr. Rajesh Narang, Derabassi

He was suffering since 2013 and had already taken over seven chemo sessions, ultimately having to hear that it is not curable. After coming to Jeena Sikho and undergoing all the treatment for a week, he is feeling much better and a hope that he will be cured.

[▶ VIEW THE VIDEO](#)

Prime Minister Narendra Modi's Brother

When Modi ji's brother came to us he used to undergo dialyses twice a week wherein 4.5 litres of water was removed from his body. Now the water content has reduced to 3 litres and he is looking forward to being free from dialysis soon.

[▶ VIEW THE VIDEO](#)

Mr. Vivek Kumar, Chandigarh

A Liver Cirrhosis patient for five years, taking multiple treatments. After getting in touch with Acharyaji, he has now stopped his allopathy medicines.

[▶ VIEW THE VIDEO](#)

Smt. Neeta Kapoor

In 2017 when she came to Jeena Sikho, her heart pulse were very low, had fatty liver, high uric acid, high lipid profile. Other doctors had advised her to use pacemaker, otherwise her heart won't function properly. She had consulted doctors across India and abroad too. But after getting in touch with Jeena Sikho, her heart pulse has improved and all other problems are in control.

[▶ VIEW THE VIDEO](#)

Mr. Vivek Oberoi

He came to Jeena Sikho seeking true wellness through balance of mind and body. Guided by Acharya Manish, he began daily Shatayu Tea and learned meditation for lasting peace and mental stability. Now, he meets challenges with self-awareness and clarity. Grateful to Acharya Manish and our team, he proudly supports our mission to uplift the health and happiness of every Indian.

[▶ VIEW THE VIDEO](#)

Mr. Rajiv Thakur

When our clients' parents came to Jeena Sikho after years of declining health, Acharya Manish's personalized Ayurvedic care began reversing chronic issues within just three months. Half of their conditions have already healed, with steady progress on the rest. More than caregivers, our team fearlessly advocates for patients, challenging medical doubt with results.

[▶ VIEW THE VIDEO](#)

Mr. Akshay Kumar

When he experienced a 14-day Ayurvedic retreat, he left behind TV, phones, and junk food—embracing white kurta-pajamas, wholesome meals. He felt lighter, more peaceful, and renewed—like discovering a hidden paradise. The experience helped him truly understand the value of traditional treatments, including Ayurvedic medicines and therapies..

[▶ VIEW THE VIDEO](#)

Mr. Ashwini Upadhyay


When top hospitals recommended knee surgery for his father, he came to our HIMS Chandigarh centre - just ten days of Ayurvedic and rehab care had his father walking pain-free, no surgery needed. These recoveries show our commitment to effective, affordable healing.

[▶ VIEW THE VIDEO](#)

Dr. Suresh Chavhanke

A respected journalist brought his father - told he needed surgery - to Jeena Sikho. Just two and a half weeks of Ayurvedic and Panchakarma care, his father's reports came back clear. A powerful example of our compassionate, evidence-based healing.

[▶ VIEW THE VIDEO](#)



05

Way
Forward



Outlook

01

IMPROVE UTILIZATION RATES OF EXISTING ASSETS

03

TAP OTC SALES CHANNEL FOR MEDICINE SALES

05

ENABLEMENT OF CASHLESS INSURANCE TO AID VOLUMES

07

OVERSEAS EXPANSION BEGINNING WITH U.A.E.

02

LAUNCH NEW CENTRES & BED ADDITION IN EXISTING CENTRES

04

EXPAND PORTFOLIO: LAUNCH NEW PRODUCTS

06

EXPECTED INCREASE IN COVERAGE UNDER GOVERNMENT PANEL / AYUSH






06

Annual


*Financial
Highlights*

Key Operating Metrics


Operational Beds & Occupancy
(#)




Avg. Revenue Per Bed*
(In ₹)




IPD Patient Volumes
(#)




OPD Patient Volumes
(# Lakh)




Medicine Order Volumes
(# Lakh)




Revenue-mix
(In ₹ Crore)




Govt. Panel Revenue
(In ₹ Crore & %)



Active Operational Centres
(#)



5Y Income Statement



(In ₹ Lakhs)

PARTICULARS	FY21	FY22	FY23	FY24	FY25
REVENUE FROM OPERATIONS	13,581	14,645	20,390	32,441	46,907
GROSS PROFIT	11,884	12,971	18,193	29,298	41,084
GROSS PROFIT MARGIN (%)	88%	89%	89%	90%	88%
OPERATING EXPENSES	10,196	11,159	13,586	19,999	28,596
EBITDA	1,688	1,812	4,608	9,299	12,488
EBITDA MARGIN (%)	12%	12%	23%	29%	27%
DEPRECIATION & AMORTISATION	246	331	313	510	871
EBIT	1,442	1,482	4,295	8,789	11,617
FINANCE COST	130	114	70	41	51
OTHER INCOME	107	149	228	644	641
PROFIT BEFORE TAXES	1,419	1,517	4,453	9,392	12,207
TAXES	389	390	1,079	2,471	3,134
PROFIT AFTER TAXES	1,029	1,127	3,374	6,921	9,073
PROFIT AFTER TAXES MARGIN (%)	8%	8%	16%	21%	19%
EARNINGS PER SHARE (₹)	10.19	11.15	13.69	27.84	36.50

Note: EPS for FY24 & FY23 takes into account bonus shares issued in November 2023


5Y Balance Sheet



(In ₹ Lakhs)

PARTICULARS	FY21	FY22	FY23	FY24	FY25
TOTAL EQUITY	2,395	3,656	12,580	19,225	27,302
NON-CURRENT LIABILITIES	92	117	63	88	302
BORROWINGS	15	81	54	32	43
CURRENT LIABILITIES	2,428	2,383	2,460	2,741	5,227
BORROWINGS	1,188	663	27	22	1,030
TRADE PAYABLES	328	463	607	446	950
TOTAL EQUITY & LIABILITIES	4,915	6,155	15,103	22,053	32,831
NON-CURRENT ASSETS	2,306	3,951	7,355	7,619	17,615
PROPERTY, PLANT AND EQUIPMENT	2,250	2,822	5,969	6,683	9,234
CAPITAL WORK-IN-PROGRESS	0	504	113	350	1,123
CURRENT ASSETS	2,609	2,204	7,748	14,434	15,216
INVENTORIES	928	576	410	350	295
TRADE RECEIVABLES	324	897	2,207	4,119	9,763
CASH AND CASH EQUIVALENTS	896	257	3,239	6,201	2,596
TOTAL ASSETS	4,915	6,155	15,103	22,053	32,831

5Y Cash Flow Statement



(In ₹ Lakhs)

PARTICULARS	FY21	FY22	FY23	FY24	FY25
CASH FROM OPERATING ACTIVITIES	1,752.76	1,747.95	1,716.94	3,668.93	6,862.68
CASH FROM INVESTING ACTIVITIES	(858.90)	(1,963.76)	(5,723.16)	(1,804.61)	(7,036.81)
CASH FROM FINANCING ACTIVITIES	(153.22)	(451.08)	4,800.34	(344.39)	(69.14)
NET CASH FLOW	740.64	(666.89)	794.12	1,519.93	(243.27)
CASH AT BEGINNING OF YEAR	143.66	884.30	217.42	1,011.54	2,531.47
CASH AT END OF YEAR	884.30	217.41	1,011.54	2,531.47	2,288.20

Market *Statistics*




NSE Symbol	<u>JSLL</u>
BSE Scrip Code	<u>544476</u>
Listing Date	
- NSE	April 19, 2022
- BSE	August 11, 2025
Current Market Price	₹654.00
52 Week High/Low	₹669.70/₹241.00
Shares Outstanding	12.43 Cr
Market Capitalization	₹8,129.27 Cr
Industry Classification	Healthcare

Note: Market Price Data as on 14th August 2025

30.30%
PUBLIC

63.53%
PROMOTERS

6.17%
FII & DII



Note: Shareholding Data as on 30th June 2025

Contact Us

CONTACT DETAILS

NANAK CHAND
CHIEF FINANCIAL OFFICER
EMAIL ADDRESS:
INVESTORS@JEENASIKHO.COM

ADDRESS:

JEENA SIKHO LIFECARE LIMITED
SCO 11, FIRST FLOOR, KALGIDHAR ENCLAVE,
KALKA SHIMLA HIGHWAY, NEAR K-AREA
ROAD, BALTANA LIGHT POINT, ZIRAKPUR,
DISTRICT MOHALI, PUNJAB - 140604



INVESTOR PRESENTATION

Q1FY26 | AUGUST 2025

THIS DOCUMENT WHICH HAVE BEEN PREPARED BY JEENA SIKHO LIFECARE LIMITED (THE "COMPANY" OR "JSLL"), HAVE BEEN PREPARED SOLELY FOR INFORMATION PURPOSES. THIS DOCUMENT HAS BEEN PREPARED BY THE COMPANY BASED ON INFORMATION AND DATA WHICH THE COMPANY CONSIDERS RELIABLE, BUT THE COMPANY MAKES NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, WHATSOEVER, AND NO RELIANCE SHALL BE PLACED ON, THE TRUTH, ACCURACY, COMPLETENESS, FAIRNESS AND REASONABLENESS OF THE CONTENTS OF THIS DOCUMENT. THIS DOCUMENT MAY NOT BE ALL INCLUSIVE AND MAY NOT CONTAIN ALL OF THE INFORMATION THAT YOU MAY CONSIDER MATERIAL. ANY LIABILITY IN RESPECT OF THE CONTENTS OF, OR ANY OMISSION FROM, THIS DOCUMENT IS EXPRESSLY EXCLUDED.

CERTAIN MATTERS DISCUSSED IN THIS DOCUMENT MAY CONTAIN STATEMENTS REGARDING THE COMPANY'S MARKET OPPORTUNITY AND BUSINESS PROSPECTS THAT ARE INDIVIDUALLY AND COLLECTIVELY FORWARD-LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS ARE NOT GUARANTEES OF FUTURE PERFORMANCE AND ARE SUBJECT TO KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND ASSUMPTIONS THAT ARE DIFFICULT TO PREDICT. THESE RISKS AND UNCERTAINTIES INCLUDE, BUT ARE NOT LIMITED TO, THE PERFORMANCE OF THE INDIAN ECONOMY AND OF THE ECONOMIES OF VARIOUS INTERNATIONAL MARKETS, THE PERFORMANCE OF THE INDUSTRY IN INDIA AND WORLD-WIDE, COMPETITION, THE COMPANY'S ABILITY TO SUCCESSFULLY IMPLEMENT ITS STRATEGY, THE COMPANY'S FUTURE LEVELS OF GROWTH AND EXPANSION, TECHNOLOGICAL IMPLEMENTATION, CHANGES AND ADVANCEMENTS, CHANGES IN REVENUE, INCOME OR CASH FLOWS, THE COMPANY'S MARKET PREFERENCES AND ITS EXPOSURE TO MARKET RISKS, AS WELL AS OTHER RISKS. THE COMPANY'S ACTUAL RESULTS, LEVELS OF ACTIVITY, PERFORMANCE OR ACHIEVEMENTS COULD DIFFER MATERIALLY AND ADVERSELY FROM RESULTS EXPRESSED IN OR IMPLIED BY THIS DOCUMENT. THE COMPANY ASSUMES NO OBLIGATION TO UPDATE ANY FORWARD-LOOKING INFORMATION CONTAINED IN THIS DOCUMENT. ANY FORWARD-LOOKING STATEMENTS AND PROJECTIONS MADE BY THIRD PARTIES INCLUDED IN THIS DOCUMENT ARE NOT ADOPTED BY THE COMPANY AND THE COMPANY IS NOT RESPONSIBLE FOR SUCH THIRD-PARTY STATEMENTS AND PROJECTIONS.